Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Immuno-Biological Laboratories Co's Debt-to-EBITDA or its related term are showing as below:
TSE:4570'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -22.32 Med: -0.65 Max: 1.84
Current: 0.46
During the past 13 years, the highest Debt-to-EBITDA Ratio of Immuno-Biological Laboratories Co was 1.84. The lowest was -22.32. And the median was -0.65.
TSE:4570's Debt-to-EBITDA is ranked better than 69.43% of 314
companies
in the Biotechnology industry
Industry Median: 1.41
vs TSE:4570: 0.46
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Immuno-Biological Laboratories Co Debt-to-EBITDA Related Terms
Immuno-Biological Laboratories Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuno-Biological Laboratories Co Debt-to-EBITDA Chart
TSE:4570 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Immuno-Biological Laboratories Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuno-Biological Laboratories Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Immuno-Biological Laboratories Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Immuno-Biological Laboratories Co (TSE:4570) has a Debt-to-EBITDA of 0.53 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Immuno-Biological Laboratories Co. According to the industry distribution chart, Immuno-Biological Laboratories Co ranks #96 out of 314 companies in the Biotechnology industry, placing it in the top 30.6%.
Is Immuno-Biological Laboratories Co's Debt-to-EBITDA too high?
Immuno-Biological Laboratories Co's current Debt-to-EBITDA is 0.53. The Biotechnology industry median Debt-to-EBITDA is 1.41. Immuno-Biological Laboratories Co's value of 0.53 is 62.4% below this industry median. Based on the distribution chart, Immuno-Biological Laboratories Co ranks #96 out of 314 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuno-Biological Laboratories Co ranks #96 out of 314 companies for Debt-to-EBITDA. This puts Immuno-Biological Laboratories Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.41. Immuno-Biological Laboratories Co's value of 0.53 is 62.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.41, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immuno-Biological Laboratories Co's current Debt-to-EBITDA of 0.53 is 62.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Immuno-Biological Laboratories Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuno-Biological Laboratories Co's current Debt-to-EBITDA is 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円588.47, compared to a current price of 円1,080.00 — trading 83.5% above its estimated fair value. The current Debt-to-EBITDA is 0.53 and 62.4% below the Biotechnology industry median of 1.41. Immuno-Biological Laboratories Co's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current Debt-to-EBITDA is 0.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued.
The current stock price of 円1,080.00 is trading 83.5% above its estimated GF Value™ of 円588.47.
GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.
Key valuation signals for TSE:4570:
Debt-to-EBITDA: 0.53
GF Value™: 円588.47 vs. price of 円1,080.00 (83.5% above fair value)
Industry Position: 62.4% below the Biotechnology median (#96 of 314)
No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
53GF Score
Get the complete analysis for TSE:4570
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4570 has been successfully added to your 
